Articles tagged "Post-transplant lymphoproliferative disorder (PTLD)"

2020 American Transplant Congress
Impact of Immunosuppression Protocol on the Incidence of EBV Viremia and PTLD in Pediatric Kidney Transplant Recipients: A Single Center Experience
K. Bowers¹, V. M. Panzarino¹, A. Campos¹, J. Buggs², V. D. Bowers²
¹Pediatrics, USF, Tampa, FL, ²Transplant Surgery, TGH, Tampa, FL
*Purpose: The purpose of this study was to evaluate the efficacy of an immunosuppression protocol change, which included avoidance of anti-thymocyte globulin for induction and…
2020 American Transplant Congress
Causal Relationship between Anti-Thymocyte Globulin Induction Therapy and Development of Monomorphic PTLD in Renal Transplant Recipients
K. Soliman¹, H. Ali², T. Fulop¹, A. Osman³, A. Halawa⁴
¹Medicine, Medical University of South Carolina, Charleston, SC, ²Medicine, Royal Stoke, Royal Stoke, United Kingdom, ³Medicine, Cairo University, Cairo, Egypt, ⁴Medicine, University of Liverpool, Liverpool, United Kingdom
*Purpose: The aim of our study is to explore the causality between ATG and different types of post-transplant lymphoproliferative disorder (PTLD) in renal transplant recipients…
2020 American Transplant Congress
Sequence Variations of the LMP1 Protein are Detected in Pediatric Transplant Recipients and May Increase the Risk of EBV Disease
B. Mbiribindi¹, M. Arvedson¹, J. Pena¹, O. Hatton², C. Esquivel¹, O. Martinez¹, S. Krams¹
¹Department of Surgery/Division of Abdominal Transplantation, Stanford Univ School of Med, Stanford, CA, ²Molecular Biology, Colorado College, Colorado Springs, CO
*Purpose: Epstein-Barr virus (EBV) infects more than 90% of adults worldwide and is associated with several malignancies, including post-transplant lymphoproliferative disorder (PTLD). PTLD is a…
2020 American Transplant Congress
Epstein-Barr Virus (EBV)+ Post-Transplant Lymphoproliferative Disorder (PTLD) is Associated with Tumor CCL3/CCL4 Expression and an Increase in Tumor-Infiltrating Monocytes
J. Toh¹, F. Vallania¹, W. A. Haynes¹, G. Bhagat², F. E. Craig³, S. H. Swerdlow⁴, T. Tousseyn⁵, S. M. Krams¹, P. Khatri¹, O. M. Martinez¹
¹Stanford University School of Medicine, Stanford, CA, ²Columbia University Medical Center, New York City, NY, ³Mayo Clinic College of Medicine, Phoenix, AZ, ⁴University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁵Katholieke Universiteit Leuven, Leuven, Belgium
*Purpose: PTLD is a serious post-transplant complication that encompasses a spectrum of abnormal lymphoproliferations, including B cell lymphoma-type PTLDs. Although many are EBV-driven, a significant…
2020 American Transplant Congress
Long-Term Safety in Epstein-Barr Virus (EBV)-Seropositive Kidney-Only Transplant Recipients Treated with Belatacept (BELA) in Clinical Practice: Final Study Results from the ENLiST Registry
C. Larsen¹, F. Vincenti², T. Kou³, C. Shadur⁴, B. Bresnahan⁵, S. Jordan⁶, E. S. Woodle⁷, N. Goes⁸, J. Vella⁹, D. Wojciechowski¹⁰, M. Polinsky³, A. Gomez-Caminero³
¹Emory University Transplant Center, Atlanta, GA, ²UCSF Transplant Center, San Francisco, CA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Iowa Kidney Physicians, Des Moines, IA, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷University of Cincinnati, Cincinnati, OH, ⁸Kaiser Permanente, San Francisco, CA, ⁹Maine Nephrology Associates, PA, Portland, ME, ¹⁰University Hospital Kidney and Liver Transplant Clinic, Dallas, TX
*Purpose: BELA, a selective T-cell costimulation blocker, is approved for the prophylaxis of organ rejection in EBV-seropositive adult kidney transplant recipients. In phase 3 BENEFIT…
2020 American Transplant Congress
Lifetime Survival Estimates Following Solid Organ Transplantation in the United States
C. Graham¹, M. Skeans², Y. Ahn², C. Watson³, A. Barlev⁴
¹RTI Health Solutions, Research Triangle Park, NC, ²Chronic Disease Research Group, Minneapolis, MN, ³Atara Biotherapeutics, South San Francisco, CA, ⁴Atara Biotherapeutics, Thousand Oaks, CA
*Purpose: The Scientific Registry of Transplant Recipients (SRTR) contains detailed patient and graft survival data for all solid organ transplants (SOT) in the United States…
2020 American Transplant Congress
Evaluation of Infectious and Malignant Complications in Elderly Renal Transplant Recipients Receiving Alemtuzumab Compared to Basiliximab
K. Lang¹, J. Shulte¹, K. Cunningham¹, C. D'Agostino¹, M. Kapugi¹, C. Kane¹, A. Novak¹, J. Leventhal²
¹Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, ²Division of Transplant Surgery, Northwestern Memorial Hospital, Chicago, IL
*Purpose: The choice of induction immunosuppression can affect several outcomes after kidney transplant (KTx), especially for elderly recipients. For this population, there is limited data…
2020 American Transplant Congress
Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte Precursors (EBV-CTLp) after Tab-cel Correlates with Response & Survival in Rituximab Relapsing or Refractory Ebv⁺ Posttransplant Lymphoproliferative Disease (PTLD)
R. Shen¹, N. Guzman-Becerra¹, Y. Sun¹, F. Forozan¹, S. Prockop², E. Doubrovina², R. O'Reilly², X. Li¹, M. Hiremath³, L. Gamelin¹, W. Navarro¹, B. Aftab¹
¹Atara Biotherapeutics, Thousand Oaks, CA, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Atara Biotherapeutics, South San Francisco, CA
*Purpose: EBV+ PTLD is often a fatal disease. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approximated…
2020 American Transplant Congress
Transplant Monitoring and PTLD Detection with B Cell Receptor Repertoire Analysis in a Large Prospective Pediatric Cohort
K. Jackson¹, O. Martinez², S. Krams², M. Robien³, M. Lapasaran², B. Armstrong⁴, C. Twist⁵, K. Weinberg⁶, D. Gratzinger¹, B. Tam¹, M. Sever⁴, M. Brown³, D. Bernstein⁶, C. Esquivel², S. D. Boyd¹
¹Department of Pathology, Stanford Univ School of Med, Stanford, CA, ²Department of Surgery/Division of Abdominal Transplantation, Stanford Univ School of Med, Stanford, CA, ³NIAID, NIH, Bethesda, MD, ⁴Rho, Chapel Hill, NC, ⁵Roswell Park, Buffalo, NY, ⁶Department of Pediatrics, Stanford Univ School of Med, Stanford, CA
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is a…
2020 American Transplant Congress
Outcomes of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders: An Analysis of the UNOS/OPTN Database (1998 to 2019)
W. Cheungpasitporn¹, C. Thongprayoon², C. C. Jadlowiec³, W. J. Chon⁴, L. S. Cummings⁴, S. R. Katari⁴, N. Leeaphorn⁴
¹Nephrology, University of Mississippi Medical Center, Jackson, MS, ²Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ³Transplant Surgery, Mayo Clinic, Phoenix, AZ, ⁴Renal Transplant Program, University of Missouri-Kansas City School of Medicine/Saint Luke's Health System, Kansas City, MO
*Purpose: Post-transplant lymphoproliferative disease (PTLD) is a serious, potentially fatal complication after kidney transplantation. Existing literature on outcomes of kidney retransplantation in patients with prior…